Three-drug combination including exenatide shows additive neuroprotection in Parkinson's disease cell models | Research

The takeaway

Among 44 drug combinations tested in Parkinson's disease cell models, only sodium phenylbutyrate + exenatide + tauroursodeoxycholic acid showed additive neuroprotective effects across four endpoints including neurite length and neuronal survival.

1 of 44 combinations worked
Only the triple combination including the GLP-1 drug exenatide improved all 4 neuroprotection endpoints in Parkinson's disease models

What the researchers found

Out of 44 combinations of 9 drugs, sodium phenylbutyrate + exenatide + tauroursodeoxycholic acid uniquely improved 4 endpoints (neurite length, branch points, live neurons, neurofilament). Tested in wild-type iPSC-derived neurons, idiopathic PD patient cells, and alpha-synuclein triplication line.

Why it matters

No current treatment slows Parkinson's disease progression. This study shows that combining drugs targeting different PD mechanisms—including the GLP-1 drug exenatide—can achieve neuroprotection superior to any single agent, potentially forming the basis for the first disease-modifying PD therapy.

How the study worked

Drug repurposing screen: 44 combinations of 9 drugs in iPSC-derived human dopaminergic neurons (wild-type + PD patient-derived + alpha-synuclein triplication) treated with MPP+. Metrics: neurite length, branch points, live neurons, neurofilament, inflammatory cytokines.

What this study cannot tell us

In vitro study—cell models cannot fully replicate human PD. MPP+ toxin model represents only one PD mechanism. Optimal doses and drug interactions in vivo unknown. Only 44 of many possible combinations tested.

How to read the evidence

Comprehensive in vitro drug screen with multiple cell models including patient-derived cells. Strong proof of concept for combination approach but needs in vivo and clinical validation.

When this study was published

Published in 2025.

The bigger picture

Parkinson's disease involves multiple pathological mechanisms (protein misfolding, oxidative stress, inflammation, mitochondrial dysfunction). This study validates the combination approach, with exenatide (a GLP-1 agonist already in PD clinical trials) as a key component.

Questions still open

Will this triple combination be tested in a clinical trial for Parkinson's disease?
Does the combination work through additive or synergistic mechanisms?
Can the approach be extended to other neurodegenerative diseases?

Common questions

Could this combination slow Parkinson's disease?

In lab-grown brain cells, the combination of sodium phenylbutyrate, exenatide (a GLP-1 drug), and TUDCA protected dopaminergic neurons better than any single drug. This is promising because it addresses multiple disease mechanisms simultaneously. However, this needs to be tested in clinical trials before we know if it works in patients.

What role does exenatide play in Parkinson's treatment?

Exenatide is a GLP-1 receptor agonist originally developed for diabetes. It has shown neuroprotective properties in several Parkinson's disease studies, including a clinical trial showing improved motor symptoms. In this combination study, it contributed to additive neuroprotection when combined with two other drugs targeting different disease pathways.

Read the original research

Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.

Antioxidants (Basel, Switzerland), 14(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Shtilbans, Alexander; Esneault, Elise; Simon, Florian; Mazzulli, Joseph R; Quiriconi, Drew J; Rom, Dror; Reintsch, Wolfgang E; Krahn, Andrea I; Durcan, Thomas M. (2025). Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.. Antioxidants (Basel, Switzerland), 14(4). https://doi.org/10.3390/antiox14040396